Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 21, 2023
Reporting Period: Specific event date (March 21, 2023)
The Company entered into an amendment to its Cooperation Agreement with Dialectic Capital Management, LP and related entities regarding changes to the composition of the Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a material definitive agreement.
Material Changes
- Board Composition: The Company agreed to appoint three individuals to the Board of Directors to fill vacancies or expand the Board size to up to 11 directors.
- Deadline: These appointments must be made no later than April 3, 2023.
- Agreement: The changes stem from an amendment to the Cooperation Agreement with Dialectic Capital Management, LP.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors beyond the context of the board restructuring. The text notes that the description of the Amendment is qualified in its entirety by reference to the full text of the Amendment filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the identities of the three individuals appointed to the Board of Directors by April 3, 2023.
- Review the full text of the Amendment to the Cooperation Agreement (Exhibit 10.1) for additional terms not summarized in this report.
- Confirm the final size of the Board of Directors following the appointments.